Takeuchi Yasuhiro
Endocrine Center, Toranomon Hospital, Tokyo, Japan.
Clin Calcium. 2017;27(4):553-559.
Primary hyperparathyroidism is a common endocrine disease. The first line therapy for the disease is surgical removal of affected parathyroid gland(s). Other therapeutic options with medication are needed to be established, because many of patients with primary hyperparathyroidism have few or no symptoms and are expected to have a long life expectancy without surgery. Cinacalcet as a calcimimetic, bisphosphonates and denosumab are promising candidates for medical management of the disease. Effectiveness and efficiency of these drugs for patients with primary hyperparathyroidism is to be evaluated in comparison with surgical treatment.
原发性甲状旁腺功能亢进是一种常见的内分泌疾病。该疾病的一线治疗方法是手术切除受影响的甲状旁腺。由于许多原发性甲状旁腺功能亢进患者很少或没有症状,并且预期不进行手术也能有较长的预期寿命,因此需要确定其他药物治疗选择。西那卡塞作为一种拟钙剂、双膦酸盐和地诺单抗是该疾病药物治疗的有前景的候选药物。这些药物对原发性甲状旁腺功能亢进患者的有效性和效率需要与手术治疗进行比较评估。